Earnings Call · Q4 FY2021·2022-02-24

Q4 21EPS -12.50%·Rev n/aQ3 21EPS -3.77%·Rev n/aQ2 21EPS -3.92%·Rev n/aQ1 21EPS -4.08%·Rev n/a⚠ consensus missing

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Sara Pellegrino — Investor Relations or Communications

Fred Vogt — Interim President and Chief Executive Officer

Igor Bilinsky — Chief Operating Officer

Jim Ziegler — Senior Vice President, Commercial

Friedrich Finckenstein — Chief Medical Officer or Head of Clinical Development

Jean-Marc Bellemin — Chief Financial Officer or Senior Financial Executive

+4.7%1d on move date+2.5% vs SPY3d+3.9%5d−5.7%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IOVA calls or request research access.

More IOVA calls Browse calls Request research access